Search

Your search keyword '"Voest, Emile E."' showing total 972 results

Search Constraints

Start Over You searched for: Author "Voest, Emile E." Remove constraint Author: "Voest, Emile E."
972 results on '"Voest, Emile E."'

Search Results

1. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice

2. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

3. Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

5. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)

7. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

8. Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics

9. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

10. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

11. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer

12. Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity

14. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

16. PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe

17. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy

18. Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol

22. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.

26. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice

28. Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.

29. Facilitating a culture of responsible and effective sharing of cancer genome data

30. Impact of genetic counselling strategy on diagnostic yield and workload for genome sequencing-based tumour diagnostics

31. Caring for patients with cancer in the COVID-19 era

32. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

34. Pan-cancer whole-genome analyses of metastatic solid tumours

35. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies

41. Supplementary Materials and Methods from Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity

42. Data from AACR Project GENIE: Powering Precision Medicine through an International Consortium

43. Supplementary Figures 1-11 from Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity

44. Table S3 from AACR Project GENIE: Powering Precision Medicine through an International Consortium

45. Data from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

46. Supplementary Figure 4 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

47. Supplementary Figure 5 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

49. Supplementary Figure 1 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

50. Supplementary Table 1 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy

Catalog

Books, media, physical & digital resources